Journals / Turkish Journal of Medical Sciences / 2022 / Cilt: 52 - Sayı: 2

The role of IL-6 and osteoprotegerin in bone metabolism in patients with Graves’ disease

Pages
338–345
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We concluded that increases in serum OPG and IL-6 levels accompanied hyperthyroidism.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Increased bone turnover is a hallmark of hyperthyroidism.
📊
Key Findings & Data:Previous studies indicated serum osteoprotegerin (OPG), receptor activator of NF-kB ligand (RANKL), and interleukin-6 (IL-6) as mediators of the effect of thyroid hormones on bone metabolism.
💡
Conclusion & Impact:We concluded that increases in serum OPG and IL-6 levels accompanied hyperthyroidism.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: Increased bone turnover is a hallmark of hyperthyroidism. The underlying factors of how thyroid hormones affect bone cells are still under the spotlight. Previous studies indicated serum osteoprotegerin (OPG), receptor activator of NF-kB ligand (RANKL), and interleukin-6 (IL-6) as mediators of the effect of thyroid hormones on bone metabolism. Ultimately, the present research aimed to examine the association of IL-6 with OPG and RANKL in patients with hyperthyroidism. Materials and methods: We carried out this study with 39 newly diagnosed and untreated Graves’ patients and 43 healthy controls. In addition to routine tests, we measured serum OPG, RANKL, and IL-6 levels. Results: Mean age and sex distribution were similar in both groups. The hyperthyroid group had significantly higher OPG (p = 0.002) and IL-6 (p < 0.001) levels, but RANKL levels were significantly lower in this group (p < 0.001). We found OPG not to correlate with free T4 and T3, while it had a moderate and negative correlation with thyrotropin (TSH) (r = -0.372, p = 0.001). IL-6 had no correlation with OPG but positively correlated with free T4 (r = 0.445, p < 0.001) and free T3 (r = 0.326, p = 0.035). It also negatively correlated with RANKL (r = –0.247, p = 0.033). Conclusion: Maintaining skeletal development and integrity is partially regulated by a normal balance of thyroid hormones. We concluded that increases in serum OPG and IL-6 levels accompanied hyperthyroidism. However, excessive levels of the hormones might cause drops in serum RANKL levels. Our results suggested that OPG, RANKL, and IL-6 might be involved in the cross-talking among immunity, thyroid function, and bone metabolism in the case of hyperthyroidism.

🔖

Cite This Article

YÜCEL, Ç., FIRAT, S. N., SERTOĞLU, E., ÖZGÜRTAŞ, T., ÇULHA, C., OMMA, T. (2022). The role of IL-6 and osteoprotegerin in bone metabolism in patients with Graves’ disease. Turkish Journal of Medical Sciences, Cilt: 52 - Sayı: 2, 338–345. https://ajindex.com/articles/609209

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Brent GA. Clinical practice. Graves’ disease. New England Journal of Medicine 2008
  2. 358(24):2594-2605. doi: 10.1056/ NEJMcp0801880 2. Brand OJ, Gough SCL. Genetics of thyroid autoimmunity and the role of the TSHR. Molecular and Cellular Endocrinology 2010
  3. 322(1-2):135-143. doi: 10.1016/j.mce.2010.01.013 3. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocrine Reviews 2003
  4. 24(6):802-835. doi: 10.1210/er.2002-0020 4. Weetman AP, Bright-Thomas R, Freeman M. Regulation of interleukin-6 release by human thyrocytes. Journal of Endocrinology 1990
  5. 127(2):357-361. doi: 10.1677/joe.0.1270357 5. Girasole G, Jilka RL, Passeri G, Boswell S, Boder G et al. 17 betaestradiol inhibits interleukin-6 production by bone marrowderived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. Journal of Clinical Investigation 1992
  6. 89(3):883-891. doi: 10.1172/ JCI115668 6. Buergi U, Larsen PR. Nuclear triiodothyronine binding in mononuclear leukocytes in normal subjects and obese patients before and after fasting. Journal of Clinical Endocrinology and Metabolism 1982
  7. 54(6):1199-1205. doi: 10.1210/jcem-54-6- 1199 7. Lakatos P, Foldes J, Horvath C, Kiss L, Tatrai A et al. Serum interleukin-6 and bone metabolism in patients with thyroid function disorders. Journal of Clinical Endocrinology and Metabolism 1997
  8. 82(1):78-81. doi: 10.1210/jcem.82.1.3641 8. Lv LF, Jia HY, Zhang HF, Hu YX. Expression level and clinical significance of IL-2, IL-6 and TGF-β in elderly patients with goiter and hyperthyroidism. European Review for Medical and Pharmacological Sciences 2017
  9. 21(20):4680-4686. 9. Anvari M, Khalilzadeh O, Esteghamati A, Momen-Heravi F, Mahmoudi M et al. Graves’ disease and gene polymorphism of TNF-α, IL-2, IL-6, IL-12, and IFN-γ. Endocrine 2010
  10. 37(2):344- 348. doi: 10.1007/s12020-010-9311-y 10. Bednarczuk T, Kuryłowicz A, Hiromatsu Y, Kiljańskic J, Telichowska A et al. Association of G-174C polymorphism of the interleukin-6 gene promoter with Graves’ ophthalmopathy. Autoimmunity 2004
  11. 37(3):223-226. doi: 10.1080/0891693042000193320 11. Akalin A, Colak O, Alatas O, Efe B. Bone remodelling markers and serum cytokines in patients with hyperthyroidism. Clinical Endocrinology (Oxford) 2002
  12. 57(1):125-129. doi: 10.1046/j.1365-2265.2002.01578.x 12. Siddiqi A, Monson JP, Wood DF, Besser GM, Burrin JM. Serum cytokines in thyrotoxicosis. Journal of Clinical Endoc